AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01442649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg IV over 90 mn on D1 every 2 weeks up to progression or toxicity
Study NCT01442649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500mg/m² on D1 every 2 weeks up to progression or toxicity
Study NCT00762190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-559 and insulin
Description: TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
Study NCT00762190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: TAK-559 placebo-matching, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
Study NCT01285778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab, mytomicin C, 5-FU, radiation
Description: Radiation therapy will be administered concurrent with chemotherapy and Panitumumab treatment. It will start the day 1 of the systemic treatment. That is, the first day of radiation therapy will be the day of the administration of the first dose of Panitumumab and Mitomycin C, as well as the first day of the first 96-hours course of 5-FU continuous infusion. On day 1, drugs and radiation will be administered in the following order:~* First, Panitumumab. Panitumumab will be administered by IV infusion on day 1, and every 2 weeks during 8 weeks~* Then Mitomycin C, 10mg/m2 on days 1 and 29~* Then start the 5-FU continuous infusion, 1000mg/m2 on days 1-4 and 29-32~* Finally, no less than 2 hours after the start of the 5-FU infusion, first dose of radiation therapy.
Study NCT05165641 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: segmental spinal anesthesia
Description: Spinal anesthesia was performed at a lower thoracic level with the patient in the sitting position. After local anesthesia with 1% lidocaine, the spinal puncture was done in the 10th thoracic intervertebral space (T 10) through a median approach. A 27 Gg pencil-point needle with an introducer was used (marquee). To identify T 10, the vertebra prominens (C7) was palpated and the spinous processes were palpated caudally \[ref}. Two senior anesthesiologists performed all the spinal punctures. The progression of the spinal needle was cautious and soft. The effort was made to stop the needle progression just after the tactile perception of the dura mater. Once the flow of cerebrospinal fluid was obtained, 1.5 ml of hyperbaric bupivacaine 5mg/ml (=7.5 mg) mixed with 0.5 ml of fentanyl 50 µg/ml (= 25 µg) was injected and the spinal needle removed.
Study NCT04541329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tildrakizumab
Description: IL-23 inhibitor
Study NCT03140540 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TEE guided fluid therapy will be administered
Description: Transesophageal echocardiography will be used to guide the fluid therapy. Velocity time integral of aorta \<20 ,200ml colloid bolus to be administered.
Study NCT03140540 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stroke volume variation guided intravenous fluid.
Description: Active Comparator: Group A control group (SVV guided fluid ) Stroke volume variation guided intraoperative intravenous fluid will be administered. SVV >10, 200 ml of colloid bolus to be given
Study NCT02330185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasonography
Description: spinal anesthesia guided with ultrasonography
Study NCT01259934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b - 1 year
Description: Induction: IFN-alpha2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alpha2b, 10 MU (flat dose), 3 days/week, SC, 12 months
Study NCT01259934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-alpha2b - 2 years
Description: Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months
Study NCT02936089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consolidation with chemotherapy (CT) or autologous hematopoietic stem cell transplantation (auto-HSCT)
Description: For CT, patients were treated with high dose cytarabine (HDAC), cytarabine at a dosage of 1-3 g/m2 q12 h ×6 doses, for 4-6 cycles.~For auto-HSCT, patients were treated with 3 cycles of HDAC and then bridged to auto-HSCT.
Study NCT02936089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consolidation with auto-HSCT or HLA-matched HSCT
Description: For auto-HSCT, patients were treated with 3 cycles of HDAC and then bridged to auto-HSCT.~For HLA-matched HSCT, patients were treated with 1-2 cycles of HDAC and then bridged to HLA-matched HSCT. HLA-matched donors were available in these patients.
Study NCT02936089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: allogeneic HSCT
Description: For allogeneic HSCT, patients were treated with 1-2 cycles of HDAC and then bridged to allogeneic HSCT, including HLA-matched and haploidentical transplantation.
Study NCT02801461 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: extracorporeal shock wave therapy
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
Study NCT02801461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: extracorporeal shock wave therapy
Description: Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (\< 10 ns) and short duration (10 μs).
Study NCT00617747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan
Description: 5mg Nasal Spray
Study NCT00617747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03412292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-40279
Description: MAX-40279, is a multi-targeted kinase inhibitor inhibitor mainly target FLT3 and FGFR. It has a molecular weight of 496.56 Daltons, which has a formula of C24H25FN6O3S.~MAX-40279 is yellow powder. It is insoluble in water, methanol, ethanol, 0.1 mol/L hydrochloride solution or 0.1% saline; very slightly soluble in methylene dichloride and sparingly soluble in dimethylformamide. It is stable under strong acid, strong alkali, high temperatures and exposure to light.~MAX-40279 for clinical use is presented as a sterile yellow powder packaged in capsules at 5 mg, or 25 mg doses.
Study NCT04120181 — intervention group
Intervention type: OTHER
Intervention: There is no intervention.
Description: There is no intervention.
Study NCT01516736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LA-EP2006
Description: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle LA-EP2006 is injected s.c. post chemotherapy application.
Study NCT01516736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta®
Description: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle Neulasta® is injected s.c. post chemotherapy application.
Study NCT04560556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Point-of-Care (POC) Rapid HIV Test
Description: Point-of-care (POC) rapid HIV testing provides results within minutes, however, it cannot reliably detect new infections. It can take up to 90 days after exposure for HIV infections to be diagnosed with POC rapid testing.
Study NCT04560556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fourth Generation Antigen/antibody (Ag/Ab) HIV Test
Description: Fourth generation laboratory-based antigen/antibody (Ag/Ab) HIV testing can detect acute HIV infections (as early as 18 days after exposure), but it takes several hours to process.
Study NCT01054495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: The acupuncture needles are inserted in PC 6 bilaterally at the acupuncture point Pericardium 6 (PC6) on each forearm (fig 2). According to the cun measurement system of Traditional Chinese Medicine (TCM), the points are located on the palmar surface of anterior forearm at a distance equivalent to the combined width of the women's middle three fingers, proximal to the most prominent wrist crease, and between the tendons of palmaris longus and flexor carpi radialis. We try to keep the depth of the needling to approximately 1,5 cm. At insertion of the acupuncture needle, DeQi is obtained and the needle is then left without any further manipulation/ stimulation (even method) in situ for 15 minutes.
Study NCT01054495 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: A sham acupuncture needle is placed at PC 6 bilaterally and the tactile stimuli of the skin during the procedure should be obtained. The sham acupuncture needle is then left at site for 15 minutes without any further manipulation/stimulation.
Study NCT01054495 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser acupuncture
Description: A laser is placed in a stand, pointing at PC 6 bilaterally, and left at site for 15 minutes without any further manipulation/stimulation.
Study NCT01465230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance lenalidomide
Description: Daily maintenance treatment, oral lenalidomide
Study NCT04485663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-010133
Description: Single or multiple doses of ALG-010133
Study NCT04485663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single or multiple doses of Placebo
Study NCT00389467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Merci Retriever and Penumbra System
Description: The MERCI (Mechanical Embolus Removal in Cerebral Ischemia) Retriever consists of a flexible, nickel titanium (nitinol) wire with a helical-shaped distal tip. The helical distal tip is covered with a platinum radiopaque coil, which facilitates fluoroscopic visualization. The body of the MERCI Retriever is covered with a hydrophilic coating that helps facilitate device placement. The MERCI Retriever is available in 6 configurations (Merci Retrievers X6, L5, L4, L6, V series, DAC).~The Penumbra System uses a reperfusion catheter in parallel with a separator component and an aspiration source to achieve separation of the thrombus and subsequent aspiration of the occlusion from the vessel. The system is available in different sizes according to the target vessels (041 Reperfusion Catheter/Separator pair for use in vessels larger than 3mm, notably the ICA and M1; 032 Reperfusion Catheter/Separator pair for use in vessels 2mm - 3mm, notably the M2).
Study NCT03999957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telehealth web conferencing
Description: Pediatric patient specific case discussions for enrolled pediatric patients at hospice staff interdisciplinary team meeting every 15 days for 60 min sessions via telehealth
Study NCT02849171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET scan
Study NCT02849171 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: C-Choline
Study NCT00620646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin, clopidogrel
Description: aspirin 100 mg plus clopidogrel 150mg qd
Study NCT00620646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin, clopidogrel, cilostazol
Description: aspirin 100mg qd,clopidogrel 75mg qd plus cilostazol 100mg bid
Study NCT00572871 — intervention group
Intervention type: OTHER
Intervention: plyometric exercise
Description: single bout of plyometric exercise
Study NCT00572871 — intervention group
Intervention type: OTHER
Intervention: resistance exercise
Description: single bout of resistance exercise
Study NCT00572871 — intervention group
Intervention type: OTHER
Intervention: No exercise
Description: Will not do any exercise
Study NCT04051697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEA CHANGE intervention
Description: The SEA CHANGE intervention consists of six 2.5 hour facilitated group workshop sessions. The sessions run over six consecutive weeks and are delivered face-to-face by a leader and peer facilitator (HNC survivor). Each session focuses on a specific self-management topic and the development/enhancement of a particular set of skills. There are opportunities for peer learning, skills practice and take-home exercises to consolidate skills development. In delivering the intervention, leaders/facilitators use a standardised approach following a leader's/facilitators' manual and participant toolkit.
Study NCT04529239 — intervention group
Intervention type: DEVICE
Intervention: Abbott Freestyle Libre Pro
Description: Continuous glucose monitoring device to analyze diabetes biomarkers.
Study NCT03274453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 0.12 mg/kg/hr of ketamine post surgery
Study NCT03274453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.12 mg/kg/hr of ketamine post surgery
Study NCT03274453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be administered at the same rate as the ketamine infusion.
Study NCT03056651 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: treatment in day-care heart failure unit
Study NCT00340704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin hydrochloride
Description: oral
Study NCT01721889 — intervention group
Intervention type: RADIATION
Intervention: Radiostereometric Analysis
Description: The radiostereometric (RSA) patient exam (flexion and extension RSA images) presents additional radiation exposure to the patient above standard of care (additional radiographs). Assuming 120kV, using three protocols (two loaded and one unloaded) per RSA exam results in a typical effective dose of approximately 2.04mSv per exam(single lumbar spine RSA at 120kV yields 0.68mSv,). HBI recommends using 140kV for lumbar spine RSA and has conducted simulations to estimate the effective dose using higher kV settings. 140kV reduces the effective dose from 0.68mSv per spine RSA to 0.2mSV, resulting in a total effective dose per RSA exam of 0.6mSv. In comparison, the estimated effective dose for a single standard lumbar spine x-ray is 1.2mSv. This additional radiation exposure is considered to be minimal risk in consideration of the number of planar x-rays the patient will undergo as part of standard care, as well as average background radiation received by humans per year (3.1mSv).
Study NCT04492059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction augmented physical therapy
Description: Using a blood flow restriction cuff during physical therapy. It is a pressurized cuff that is used to decrease the amount of oxygen that is available to the muscle during exercise. This stimulates the muscle to believe it is in an anoxic state and can produce greater strength and hypertrophy with fewer reps and less weight which would mean less stress on a surgically repaired tendon.
Study NCT04492059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Completing traditional physical therapy.
Study NCT02018653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Alumina-Silicate (CASAD)
Description: 1 gram by mouth every 6 hours for up to 6 days.
Study NCT02018653 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 by mouth every 6 hours for up to 6 days.
Study NCT02018653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Questionnaire completion at baseline about diarrhea and other symptoms.
Study NCT02018653 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire
Description: Questionnaire completion at baseline about diarrhea and other symptoms.
Study NCT00567840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA-824
Description: 200 mg, 600 mg, 100 mg, 1200 mg qd
Study NCT00567840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PA-824
Description: 200 mg, 600 mg, 100 mg, 1200 mg qd
Study NCT02134938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Konjac Glucomannan
Description: Konjac Noodles (Wellbond Import Export Inc.), Vegan Konjac Shrimp (Sophie's Kitchen), Konjac Gel Cubes
Study NCT01861002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacytidine
Description: Dose assigned at study entry (75 mg/m2/day). Given subcutaneously, once daily on days 1 to 5, for a total of 5 doses.
Study NCT01861002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 6 to 10, total 5 doses
Study NCT01861002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2000 mg/m2/dose intravenous infusion over 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 6 to 10, total 5 doses.
Study NCT01861002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT) Cytarabine
Description: Intrathecally to AML patients on day 1 of course 1 and 2.~* Omit on day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~* IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~* For patients with CNS disease, IT cytarabine can be given weekly until the CSF is clear. Two additional doses of IT cytarabine should be given weekly after the initial CSF clearing. It is permitted to change to intrathecal triple therapy (ITT) if persistent blasts are present in the CSF based on the treating physician's clinical judgment. Cytarabine dose defined by age:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients >3 years of age~ITT Dosing:~Age (yrs) - Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~1. - 1.99 MTX: 8 mg, HC: 15 mg, ARAC: 30 mg~2. - 2.99 MTX: 10 mg, HC: 25 mg, ARAC: 50 mg~   * 3 - MTX: 12 mg, HC: 35 mg, ARAC: 70 mg
Study NCT01861002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Methotrexate (IT MTX)
Description: * Intrathecally to patients with ALL on day 1 of course 1 and 2.~* Omit IT MTX on Day 1 of course 1 if patient received IT therapy within 7 days prior to study enrollment~* IT therapy may be given during the end of course 1 disease evaluation and repeated every 7 days~* For patients with CNS 2 or 3 disease, IT MTX can be given weekly until the CSF is clear. Two additional doses of IT MTX should be given weekly after the initial clearing of the CSF. It is permitted to change to ITT if persistent blasts are present in the CSF. Methotrexate dose defined by age~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients >9 years of age~Triple IT Therapy Dosing:~Age (yrs): Dose Methotrexate (MTX), Hydrocortisone (HC), Cytarabine (ARAC):~1. - 1.99 MTX: 8 mg, HC: 8 mg, ARAC: 16 mg~2. - 2.99 MTX: 10 mg, HC: 10 mg, ARAC: 20 mg~3. - 8.99 MTX: 12 mg, HC: 12 mg, ARAC: 24 mg~   * 9 MTX: 15 mg, HC: 15 mg, ARAC: 30 mg
Study NCT01675674 — intervention group
Intervention type: OTHER
Intervention: Dried blood spot test for MPS
Description: The dried blood spot test uses a few drops of blood on filter paper to screen for mucopolysaccharidoses (MPS I, MPS II, MPS IVA and MPS VI in this study).
Study NCT03670511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sit-to-stand test
Description: to sit and stand from a chair
Study NCT03670511 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: six minute walking test
Description: to walk for six minutes
Study NCT00184002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone
Description: Cycle 1 Doxil 40 mg/m2 iv day 1 over a minimum of 60 min.~Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min.~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum).~Prednisone 100 mg po days 1-5.~Cycle 2 until study completion~Doxil 40 mg/m2 iv day 1~Rituxan 375 mg/m2 iv day 1~Cyclophosphamide 750 mg/m2 iv day 1~Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum)~Prednisone 100 mg po days 1-5~* 1 cycle = 21 days.~* Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles.
Study NCT00556257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Standard of care
Study NCT00556257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690-,550
Description: CP-690550 20 mg BID in Months 1-6 then 15 mg BID in Months 7-12
Study NCT03291951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: The intervention goal is for study participants to exercise with progressively higher weights for resistance training to achieve a 1-kg increase in lean body mass by the end of the intervention. During an in-person visit on the same day as a chemotherapy infusion session, exercise professionals will teach participants a series of exercises to be completed at home twice weekly throughout the intervention. Participants will also receive protein powder, which they will be instructed to consume with meals twice a day. During subsequent infusion sessions, the exercise professional will meet in-person with participants to evaluate their ability to increase weights, and adjust exercises appropriately. In between visits, the exercise professional will check-in with participants by phone.
Study NCT04628000 — intervention group
Intervention type: OTHER
Intervention: Vitamin D
Description: Clinical Correlation
Study NCT00828061 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of 5 tablets matching placebo (5 x 0 mg) to prednisone. The washout between treatment periods will be approximately 4 weeks
Study NCT00828061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Single dose of 5 tablets prednisone totaling 10 mg (3 x 0 mg + 2 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
Study NCT00828061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Single dose of 5 tablets prednisone totaling 25 mg (5 x 5 mg). The washout between treatment periods will be approximately 4 weeks.